Literature DB >> 9702423

Combined use of a fasting plasma glucose concentration and HbA1c or fructosamine predicts the likelihood of having diabetes in high-risk subjects.

G T Ko1, J C Chan, V T Yeung, C C Chow, L W Tsang, J K Li, W Y So, H P Wai, C S Cockram.   

Abstract

OBJECTIVE: To assess the validity of using fasting plasma glucose (FPG) concentrations in conjunction with HbA1c or fructosamine for the screening of diabetes in high-risk individuals. RESEARCH DESIGN AND METHODS: In this study 2,877 Hong Kong Chinese (565 [19.6%] men; 2,312 [80.4%] women) with various risk factors for glucose intolerance underwent a 75-g oral glucose tolerance test (OGTT) for screening of diabetes. The risk factors included a family history positive for diabetes, a history of gestational diabetes or impaired glucose tolerance, and obesity.
RESULTS: Using World Health Organization (WHO) criteria, 1,593 (55.4%) had normal glucose tolerance, 657 (22.8%) had impaired glucose tolerance, and 627 (21.8%) had diabetes. When the 1997 American Diabetes Association (ADA) criteria were applied, 394 (13.7%) had diabetes with an FPG > or = 7.0 mmol/l. Using multiple receiver operating characteristic curve analysis, the paired values of an FPG of 5.6 mmol/l and a HbA1c of 5.5% gave an optimal sensitivity of 83.8% and specificity of 83.6% to predict a 2-h plasma glucose (PG) > or = 11.1 mmol/l. Likewise, the paired values of an FPG of 5.4 mmol/l and a fructosamine level of 235 mumol/l (n = 2,408) gave an optimal sensitivity of 81.5% and specificity of 83.2%. An FPG > or = 5.6 mmol/l and an HbA1c > or = 5.5% was 5.4-fold more likely to occur in diabetic subjects (based on the WHO criteria) compared with nondiabetic subjects. For paired parameters less than these values, the likelihood ratio of this occurring in diabetic subjects was only 0.11. Similarly, an FPG > or = 5.4 mmol/l and a fructosamine > or = 235 mumol/l was fivefold more likely to occur in diabetic subjects than in nondiabetic subjects, with both parameters less than these values having a likelihood ratio of 0.04. Using these paired values as initial screening tests, only subjects who had an FPG > or = 5.6 mmol/l and < 7.8 mmol/l and an HbA1c > or = 5.5% (n = 642) required an OGTT to confirm diabetes, thereby saving 77.7% [(2,877-642)/2,877] of the OGTTs performed. Similarly, only subjects who had an FPG > or = 5.4 mmol/l and < 7.8 mmol/l and a fructosamine > or = 235 mumol/l (n = 526) required OGTT to confirm diabetes, meaning that 78.2% [(2,408-526)/2,408] of the OGTTs could have been saved. Based on the 1997 ADA criterion of an FPG cutoff value of 7.0 mmol/l, the corresponding numbers of OGTTs to be saved were 82.6% and 85.5%, respectively.
CONCLUSIONS: The paired values of FPG and HbA1c or FPG and fructosamine helped to identify potentially diabetic subjects, the diagnosis of which could be further confirmed by the 75-g OGTT. Using this approach approximately 80% of OGTTs could have been saved, depending on the diagnostic cutoff value of FPG.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9702423     DOI: 10.2337/diacare.21.8.1221

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  22 in total

1.  Comparative performance of HbA1c 6.5% for FPG ≥7.0 vs 2hr PG≥11.1 criteria for diagnosis of type 2 diabetes.

Authors:  A N Adamu
Journal:  Afr Health Sci       Date:  2011-09       Impact factor: 0.927

2.  [Do the new criteria of the American Diabetes Association lead to earlier diagnosis of type-2 diabetes mellitus?].

Authors:  M Mata Cases; X Cos Claramunt; E Pujol Ribera; I Bobé Molina; R Centelles Fernández; R Ortiz López; A Ramos Fuertes; C Royo Pastor
Journal:  Aten Primaria       Date:  2001-06-15       Impact factor: 1.137

3.  Diabetes screening in overweight and obese children and adolescents: choosing the right test.

Authors:  Stefan Ehehalt; Susanna Wiegand; Antje Körner; Roland Schweizer; Klaus-Peter Liesenkötter; Carl-Joachim Partsch; Gunnar Blumenstock; Ulrike Spielau; Christian Denzer; Michael B Ranke; Andreas Neu; Gerhard Binder; Martin Wabitsch; Wieland Kiess; Thomas Reinehr
Journal:  Eur J Pediatr       Date:  2016-11-25       Impact factor: 3.183

4.  HbA(1c) values for defining diabetes and impaired fasting glucose in Asian Indians.

Authors:  Manisha Nair; Dorairaj Prabhakaran; K M Venkat Narayan; Rashmi Sinha; Ramakrishnan Lakshmy; Niveditha Devasenapathy; Carrie R Daniel; Ruby Gupta; Preethi S George; Aleyamma Mathew; Nikhil Tandon; K Srinath Reddy
Journal:  Prim Care Diabetes       Date:  2011-04-06       Impact factor: 2.459

5.  Association of fructosamine to indices of dyslipidemia in older adults with type 2 diabetes.

Authors:  Kim E Innes; Terry Kit Selfe; Abhishek Vishnu
Journal:  Diabetes Metab Syndr       Date:  2010-12-30

6.  Glycated haemoglobin A1c for diagnosing diabetes in Chinese population: cross sectional epidemiological survey.

Authors:  Yuqian Bao; Xiaojing Ma; Huating Li; Mi Zhou; Cheng Hu; Haiya Wu; Junling Tang; Xuhong Hou; Kunsan Xiang; Weiping Jia
Journal:  BMJ       Date:  2010-05-17

7.  Pressure pain precedes development of type 2 disease in Zucker rat model of diabetes.

Authors:  Dmitry Romanovsky; James C Walker; Maxim Dobretsov
Journal:  Neurosci Lett       Date:  2008-09-05       Impact factor: 3.046

8.  Paired values of serum fructosamine and blood glucose for the screening of gestational diabetes mellitus: A retrospective study of 165 Saudi pregnant women.

Authors:  Haseeb Ahmad Khan; Samia Hasan Sobki; Abdullah Saleh Alhomida; Shaukat Ali Khan
Journal:  Indian J Clin Biochem       Date:  2007-03

9.  Developing a Screening Algorithm for Type II Diabetes Mellitus in the Resource-Limited Setting of Rural Tanzania.

Authors:  Caroline West; David Ploth; Virginia Fonner; Jessie Mbwambo; Francis Fredrick; Michael Sweat
Journal:  Am J Med Sci       Date:  2016-02-10       Impact factor: 2.378

10.  Performance of an A1C and fasting capillary blood glucose test for screening newly diagnosed diabetes and pre-diabetes defined by an oral glucose tolerance test in Qingdao, China.

Authors:  Xianghai Zhou; Zengchang Pang; Weiguo Gao; Shaojie Wang; Lei Zhang; Feng Ning; Qing Qiao
Journal:  Diabetes Care       Date:  2009-12-10       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.